Endoluminal radiofrequency ablation of malignant biliary
stenoses

a 2015

Endoluminal radiofrequency ablation of malignant biliary stenoses

ANDRAŠINA, Tomáš, Jiří PÁNEK, Jan HLAVSA, Vladan BERNARD, Vlastimil VÁLEK et. al.

Basic information

Original name

Endoluminal radiofrequency ablation of malignant biliary stenoses

Authors

ANDRAŠINA, Tomáš (703 Slovakia, guarantor, belonging to the institution), Jiří PÁNEK (203 Czech Republic, belonging to the institution), Jan HLAVSA (203 Czech Republic, belonging to the institution), Vladan BERNARD (203 Czech Republic, belonging to the institution) and Vlastimil VÁLEK (203 Czech Republic, belonging to the institution)

Edition

European Congress of Radiology 2015, 2015

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Austria

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/15:00087460

Organization unit

Faculty of Medicine

ISSN

DOI

http://dx.doi.org/10.1007/s13244-015-0387-z

Keywords in English

endoluminal ablation biliary

Abstract

V originále

Purpose: To prove efficacy of endoluminal radiofrequency ablation before stenting of malignant biliary stenoses. Methods and Materials: 54 patients with histologically proven malignant biliary stenoses have been enrolled in a prospective randomised study from 2010. 73 non-covered self-expandable metal stents were inserted. In group A (n=22) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB;EMcision Ltd.,London,UK) was performed 0-48hours prior to the stent insertion, in group B (n=32) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meyer analysis). Results: No major complications related to the stent insertion and endoluminal ablation were recorded. 30 day mortality was 3.7%. The average primary stent patency was 5.6 and 5.2 months in group A and B, respectively, 3-months and 6-months stent failure was 9.1% and 13.6% in group A and 15% and 25% in group B. The median survival from the insertion of the stent was 5.9 (2.9-6.7) and 5.4 (3.7-8.6) months, the median survival from the initial drainage was 9.6 (5.6-12.2) and 8.5 (5.8-12.7) months in group A and B, respectively. The difference was not statistically significant. Conclusion: In the prospective randomised clinical study the effect of an endoluminal ablation on patients survival was not proven. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. In addition, the intervention was not associated with higher rates of complications.

Links

NT14586, research and development project

Name: Choledochoskopem navigovaná radiofrekvenční ablace žlučových cest.

Investor: Ministry of Health of the CR

Citovat

ANDRAŠINA, Tomáš, Jiří PÁNEK, Jan HLAVSA, Vladan BERNARD and Vlastimil VÁLEK. Endoluminal radiofrequency ablation of malignant biliary stenoses. In European Congress of Radiology 2015. 2015. ISSN 1869-4101. Available from: https://dx.doi.org/10.1007/s13244-015-0387-z.

@proceedings{1317130,
   author = {Andrašina, Tomáš and Pánek, Jiří and Hlavsa, Jan and Bernard, Vladan and Válek, Vlastimil},
   booktitle = {European Congress of Radiology 2015},
   doi = {http://dx.doi.org/10.1007/s13244-015-0387-z},
   keywords = {endoluminal ablation biliary},
   language = {eng},
   title = {Endoluminal radiofrequency ablation of malignant biliary stenoses},
   year = {2015}
}

TY  - CONF
ID  - 1317130
AU  - Andrašina, Tomáš - Pánek, Jiří - Hlavsa, Jan - Bernard, Vladan - Válek, Vlastimil
PY  - 2015
TI  - Endoluminal radiofrequency ablation of malignant biliary stenoses
KW  - endoluminal ablation biliary
N2  - Purpose: To prove efficacy of endoluminal radiofrequency ablation before stenting of malignant biliary stenoses. Methods and Materials: 54 patients with histologically proven malignant biliary stenoses have been enrolled in a prospective randomised study from 2010. 73 non-covered self-expandable metal stents were inserted. In group A (n=22) the endoluminal ablation with a bipolar radiofrequency catheter (EndoHPB;EMcision Ltd.,London,UK) was performed 0-48hours prior to the stent insertion, in group B (n=32) the stent was implanted without a prior ablation. The primary endpoints of the study were to determine the rate of complications, duration of stent patency and survival of patients (Kaplan-Meyer analysis). Results: No major complications related to the stent insertion and endoluminal ablation were recorded. 30 day mortality was 3.7%. The average primary stent patency was 5.6 and 5.2 months in group A and B, respectively, 3-months and 6-months stent failure was 9.1% and 13.6% in group A and 15% and 25% in group B. The median survival from the insertion of the stent was 5.9 (2.9-6.7) and 5.4 (3.7-8.6) months, the median survival from the initial drainage was 9.6 (5.6-12.2) and 8.5 (5.8-12.7) months in group A and B, respectively. The difference was not statistically significant. Conclusion: In the prospective randomised clinical study the effect of an endoluminal ablation on patients survival was not proven. However, in the group of patients undergoing ablation there is a tendency of a lower rate of early stent failure. In addition, the intervention was not associated with higher rates of complications.
ER  -

ANDRAŠINA, Tomáš, Jiří PÁNEK, Jan HLAVSA, Vladan BERNARD and Vlastimil VÁLEK. Endoluminal radiofrequency ablation of malignant biliary stenoses. In \textit{European Congress of Radiology 2015}. 2015. ISSN~1869-4101. Available from: https://dx.doi.org/10.1007/s13244-015-0387-z.

Detailed Information on Publication Record